Strikingly, after 2 vaccine doses, patients with IBD treated with anti-TNF demonstrated significantly lower frequencies of S-specific cMBCs compared with patients with IBD treated with anti-IL-12/23 and lower frequencies of S-specific DN2 CD11c+ aMBCs and cMBCs compared with people in the healthy control group (Figure 3, B and C). This evidence concerns the gene ITGAX and inflammatory bowel disease.